Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis

Pharmacogenomics. 2015;16(7):713-20. doi: 10.2217/pgs.15.34. Epub 2015 May 7.

Abstract

Objective: To assess if the allelic variations of rs16969968/rs1051730 in the CHRNA5-CHRNA3-CHRNB4 gene cluster are associated with smoking cessation after nicotine replacement therapy (NRT).

Methods: We searched for NRT studies published from 2000-2013 that reported counts for allelic variation of rs16969968/rs1051730 and measured abstinence rates at the end of NRT treatment. We identified four studies which met the criteria, giving us a test sample of 2036 participants.

Results: There was no effect of rs16969968/rs1051730 in influencing the success rate at the end of NRT (n = 6, effect size [ES]: 0.969, 95% CI: 0.77 to 1.23, z = 0.27, p = 0.791).

Conclusion: There is no robust evidence that allelic variations of rs16969968 or rs1051730 are associated with smoking cessation after NRT. Original submitted 26 November 2014; Revision submitted 9 March 2015.

Keywords: CHRNA3; CHRNA5; NRT; genetics; smoking.

Publication types

  • Meta-Analysis

MeSH terms

  • Clinical Trials as Topic / methods
  • Genetic Variation / drug effects
  • Genetic Variation / genetics*
  • Humans
  • Smoking / drug therapy*
  • Smoking / genetics*
  • Smoking Cessation* / methods
  • Tobacco Use Cessation Devices*